Companies › Matrix Biomed
1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular, Gastroenterology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tempol Free radical scavenger and antioxidant | – | Phase 2 | Mucositis; Healthy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03480971 | Tempol | Phase 2 | Mucositis | Gastroenterology | Jul 2025 |
| NCT06424756 | Tempol | Phase 2 | Healthy | Cardiovascular | Mar 2030 |
No annotated target.
–
Livzon Pharmaceutical Group Noorik Biopharmaceuticals Tectonic Operating Company CuraSen Therapeutics Neurimmune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.